ClinicalTrials.gg
Not yet recruitingNCT06594172Updated Sep 19, 2024

Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

A Phase 2 interventional study of Memantine Oral Tablet and Pioglitazone 15mg in Radiation Disease, Cognitive Impairment and Drug Effect, sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing memantine in Cognitive Dysfunction — 2 open to participants now, 2 under way, none of them phase 3. Memantine · Cognitive Dysfunction.

Planned enrollment
8th of 15
67 · median 67
Started
2024
the only one that year
Phase 2
5 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Among the 15 studies testing memantine in Cognitive Dysfunction, this one is the 8th largest by planned enrollment, is the only one that started in 2024, is one of 5 in phase 2, and was the 14th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

2 of the 15 studies testing memantine in Cognitive Dysfunction are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing memantine in Cognitive Dysfunction, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the efficacy of early intervention with Memantine and Pioglitazone in preventing Radiation-Induced Brain Injury (RIBI) in patients undergoing cranial radiotherapy.

RIBI, a significant complication of radiation therapy for primary and metastatic brain tumors, as well as head and neck cancers, often presents with delayed and irreversible neurological damage, severely affecting patients' quality of life.

Our previous studies have indicated that Memantine, an NMDAR antagonist, and Pioglitazone, a PPAR-γ agonist, play crucial roles in modulating the neuroprotective immune microenvironment by targeting key mechanisms of neuron-astrocyte fatty acid metabolism coupling. These findings suggest that early administration of these drugs could protect cognitive function and reduce neuroinflammation in patients post-radiation.

This prospective phase II clinical trial will assess the combined efficacy of Memantine and Pioglitazone in improving cognitive outcomes and preventing RIBI without adversely impacting the anti-tumor efficacy of radiation therapy. The study will also explore the synergistic effects of these two FDA-approved drugs in early-stage RIBI prevention, providing a new therapeutic strategy for enhancing the quality of life in cancer patients receiving radiotherapy.

03

Conditions studied

  • Radiation Disease
  • Cognitive Impairment
  • Drug Effect

Keywords

  • radiation induced brain injury
  • Memantine
  • Pioglitazone
  • cognitive function
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recursive Partitioning Analysis (RPA), Class I \~ Class II
  • Performance Status of ≥70
  • The primary tumor must be confirmed. For newly diagnosed , the number of is not limited, but the brain metastases could not have been within 5 mm of hippocampus. Additionally, there must be no hard or soft meningeal metastases.
  • No history of whole-brain radiation therapy; patients who are eligible for surgical resection of brain metastases prior to radiation therapy are allowed.
  • Bone marrow function: White blood cell count ≥ 4 × 10⁹/L, ≥ 90 g/L, and count ≥ 100 × 10⁹/L.
  • Adequate hepatic function: Total ≤ 1.5 × (Upper Limit of Normal); (alanine aminotransferase), AST (aspartate aminotransferase) ≤ 2.5 × ULN; ALP (alkaline phosphatase) ≤ 2.5 × ULN and total bilirubin ≤ ULN.
  • Adequate renal function: rate ≥ 30 ml/min.
  • Patients or their legal guardians voluntarily participate and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Radiographic evidence of hydrocephalus or other architectural distortion of the ventricular system, including placement of external ventricular drain or ventriculoperitoneal shunt.
  • Planned cytotoxic chemotherapy during the WBRT.
  • Pregnant or lactating women (Women of childbearing age must undergo a pregnancy test; effective must be enforced during the treatment period).
  • Previous cranial radiation therapy (Except for patients with head and neck cancer where the disease site is outside the cranial radiation field).
  • Severe or active symptomatic cardiopulmonary diseases; psychiatric disorders; Personality or psychiatric disease; Severe hepatic disease defined as a diagnosis of class B or C hepatic disease;
  • Intolerant to or allergic to Memantine or pioglitazone.
  • Difficulty swallowing, chronic diarrhea, or bowel obstruction.
  • class III or IV heart failure or symptomatic peripheral edema (grade 2 or higher); those treated with insulin or oral hypoglycemic agents for -induced hyperglycemia, or those currently using other NMDA antagonists.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    MPR

    combined Memantine and Pioglitazone with radiation therapy

    Drug: Memantine Oral Tablet · Drug: Pioglitazone 15mg · Radiation: Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)

Interventions

  • DrugMemantineStudies of MemantineMemantine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of Memantine Tablets (10mg/tablet): Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily.

    Also known as: pioglitazone, hippocampal avoidance whole-brain radiotherapy (HA-WBRT)

  • DrugPioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet): Weeks 1-24: 30mg once daily.

  • RadiationHippocampal avoidance whole-brain radiotherapy (HA-WBRT)

    Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).

06

What researchers measure

Primary outcomes

  1. the cumulative incidence of cognitive failure

    the proportion of participants who experience cognitive impairments after radiation therapy

    Time frame: At weeks 4, 8, 16, 24, 36, and 48 after the completion of radiotherapy

Secondary outcomes

  1. Cognitive Score Decline

    based on the Reliable Change Index of at least one cognitive test

    Time frame: At weeks 4, 8, 16, 24, 36, and 48 after the completion of radiotherapy

  2. Progressive-free survival for Intracranial Tumors

    latencies to the first intracranial treatment failure or death from any cause

    Time frame: At weeks 4, 8, 16, 24, 36, and 48 after the completion of radiotherapy

  3. Overall Survival

    death due to any cause

    Time frame: At weeks 4, 8, 16, 24, 36, and 48 after the completion of radiotherapy

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2025, 15 months later.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 15 months is below that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartEst.
Sep 10, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 30, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06594172
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborators
Guangdong Provincial People's Hospital, Fujian Medical University Union Hospital, Southern Medical University, China, The Affiliated Panyu Center Hospital of Guangzhou Medical University, The Central Hospital of Shaoyang City
Responsible party
Yuan yawei (The Chair of the Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University) — Principal investigator
First posted
Sep 19, 2024
Start date
Sep 10, 2024 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 19, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Memantine · Pioglitazone

Start the discussion